Lubiprostone is a prescription medication used to treat three types of constipation: chronic idiopathic constipation (CIC) in adults, opioid-induced constipation (OIC) in adults with chronic non-cancer pain, and irritable bowel syndrome with constipation (IBS-C) in women 18 and older. First approved by the FDA in 2006, it’s sold under the brand name Amitiza and works by pulling more fluid into the intestines to soften stool and stimulate bowel movements.
The Three Conditions Lubiprostone Treats
Chronic idiopathic constipation is the broadest of the three approved uses. “Idiopathic” simply means there’s no identifiable underlying cause. You’re not constipated because of a medication, a hormonal issue, or a structural problem. Your gut just moves too slowly, and lubiprostone helps correct that. This indication applies to all adults regardless of sex.
Opioid-induced constipation is exactly what it sounds like: constipation caused by opioid pain medications. Opioids slow the muscles of the digestive tract as a side effect, and the problem doesn’t resolve on its own as long as you’re taking the medication. Lubiprostone is approved specifically for people with chronic non-cancer pain, including those whose pain originally stemmed from cancer or cancer treatment but who no longer need frequent dose increases. One important limitation: its effectiveness has not been established in people taking methadone or other diphenylheptane opioids. Lab studies show these opioids can interfere with how lubiprostone works at the cellular level, potentially reducing its benefit in a dose-dependent way.
Irritable bowel syndrome with constipation (IBS-C) is the most narrowly approved use. Lubiprostone is only indicated for women 18 and older with this condition. The reason is straightforward: fewer than 10% of participants in the major clinical trials were men, so the FDA concluded there wasn’t enough data to confirm it works the same way in males. For chronic idiopathic constipation, the FDA felt comfortable extending results from women to men because that condition is better understood, but IBS-C involves more complex and variable mechanisms.
Lubiprostone is not approved for children. A trial of over 600 children ages 6 to 17 with functional constipation failed to show a meaningful difference from placebo.
How It Works in the Gut
Lubiprostone increases the amount of chloride-rich fluid secreted into your intestines. It does this by activating a specific protein channel on the cells lining the gut wall. When more chloride flows into the intestinal space, water follows, which softens stool and makes it easier to pass. The drug also appears to stimulate a receptor involved in signaling that promotes this fluid secretion. Importantly, this mechanism is local to the gut rather than systemic, meaning it targets the digestive tract directly rather than working through the bloodstream or nervous system.
How Quickly It Works
Lubiprostone tends to produce results fast. In pooled clinical trial data for chronic constipation, 60% of patients had a spontaneous bowel movement within 24 hours of their first dose, compared to 35% on placebo. By the 48-hour mark, that number rose to 80%. So most people notice a change within the first day or two, though individual responses vary.
Dosing Differences by Condition
The dose depends on which condition is being treated. For chronic idiopathic constipation and opioid-induced constipation, the standard dose is 24 micrograms taken twice daily. For IBS-C, the dose is significantly lower at 8 micrograms twice daily. In both cases, the capsules are taken with food and water, which is important because eating alongside the medication helps reduce the most common side effect: nausea.
Nausea and Other Side Effects
Nausea is by far the most frequently reported side effect, and the rate varies sharply depending on the dose. At the higher dose used for chronic constipation (24 mcg twice daily), roughly 29% of patients in clinical trials experienced nausea. About 4% described it as severe, and 9% stopped taking the medication because of it. The relationship is dose-dependent: when the same amount was given only once daily instead of twice, the nausea rate dropped to 17%.
At the lower IBS-C dose (8 mcg twice daily), nausea affected only about 8% of patients, making it much more tolerable. Taking the capsule with food is the simplest way to minimize this effect. Other side effects reported in trials included diarrhea, headache, and abdominal discomfort, though these occurred less frequently than nausea.
Who Should Not Take Lubiprostone
Lubiprostone should not be used if you have a known or suspected mechanical bowel obstruction, meaning a physical blockage in the intestines. The medication works by increasing fluid secretion, and adding fluid behind a blockage could worsen the situation. People with significant liver impairment may also need dose adjustments, as the drug is processed differently in those with reduced liver function.